Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -68.06 Million USD | -72.8% |
| 2022 | -31.71 Million USD | -39.73% |
| 2021 | -22.69 Million USD | 5.11% |
| 2020 | -23.92 Million USD | -90.61% |
| 2019 | -12.54 Million USD | -11.1% |
| 2018 | -11.29 Million USD | 50.83% |
| 2017 | -22.97 Million USD | -168.22% |
| 2016 | -8.56 Million USD | -10.22% |
| 2015 | -7.77 Million USD | 59.34% |
| 2014 | -19.11 Million USD | 53.55% |
| 2013 | -41.14 Million USD | -34.85% |
| 2012 | -30.51 Million USD | -91.82% |
| 2011 | -15.9 Million USD | -123.29% |
| 2010 | -7.12 Million USD | 61.21% |
| 2009 | -18.36 Million USD | 58.23% |
| 2008 | -43.97 Million USD | -14.68% |
| 2007 | -38.34 Million USD | -103.78% |
| 2006 | -18.81 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -22.56 Million USD | -89.83% |
| 2024 Q3 | -16.55 Million USD | 26.63% |
| 2024 Q1 | -11.88 Million USD | -4330.6% |
| 2023 FY | -54.8 Million USD | -72.8% |
| 2023 Q4 | 281 Thousand USD | 100.88% |
| 2023 Q2 | -12.62 Million USD | 46.65% |
| 2023 Q3 | -32.06 Million USD | -153.92% |
| 2023 Q1 | -23.66 Million USD | -134.68% |
| 2022 Q4 | -10.08 Million USD | 5.19% |
| 2022 Q3 | -10.63 Million USD | -307.67% |
| 2022 Q1 | -8.3 Million USD | 20.03% |
| 2022 Q2 | -2.6 Million USD | 68.59% |
| 2022 FY | -31.71 Million USD | -39.73% |
| 2021 Q3 | 1.33 Million USD | 129.65% |
| 2021 Q1 | -9.15 Million USD | -133.43% |
| 2021 Q4 | -10.38 Million USD | -880.83% |
| 2021 FY | -22.69 Million USD | 5.11% |
| 2021 Q2 | -4.48 Million USD | 51.0% |
| 2020 Q4 | -3.92 Million USD | 35.32% |
| 2020 FY | -23.92 Million USD | -90.61% |
| 2020 Q2 | -6.1 Million USD | 21.98% |
| 2020 Q1 | -7.82 Million USD | -727.38% |
| 2020 Q3 | -6.06 Million USD | 0.7% |
| 2019 Q2 | -6.62 Million USD | -26.42% |
| 2019 Q3 | 259 Thousand USD | 103.91% |
| 2019 FY | -12.54 Million USD | -11.1% |
| 2019 Q1 | -5.23 Million USD | -713.51% |
| 2019 Q4 | -946 Thousand USD | -465.25% |
| 2018 Q1 | -4.7 Million USD | -635.49% |
| 2018 Q4 | -644 Thousand USD | 69.42% |
| 2018 FY | -11.29 Million USD | 50.83% |
| 2018 Q3 | -2.1 Million USD | 45.13% |
| 2018 Q2 | -3.83 Million USD | 18.46% |
| 2017 Q1 | -7.47 Million USD | -42.4% |
| 2017 Q3 | -10.03 Million USD | -58.37% |
| 2017 Q2 | -6.33 Million USD | 15.24% |
| 2017 FY | -22.97 Million USD | -168.22% |
| 2017 Q4 | 879 Thousand USD | 108.76% |
| 2016 Q3 | 1.41 Million USD | -36.95% |
| 2016 FY | -8.56 Million USD | -10.22% |
| 2016 Q4 | -5.25 Million USD | -470.24% |
| 2016 Q2 | 2.24 Million USD | 132.22% |
| 2016 Q1 | -6.98 Million USD | -212.63% |
| 2015 FY | -7.77 Million USD | 59.34% |
| 2015 Q2 | -5.69 Million USD | -3.06% |
| 2015 Q1 | -5.52 Million USD | -1328.67% |
| 2015 Q3 | 5.69 Million USD | 199.86% |
| 2015 Q4 | -2.23 Million USD | -139.24% |
| 2014 Q1 | -6.39 Million USD | 35.07% |
| 2014 Q2 | -8.91 Million USD | -39.32% |
| 2014 Q3 | -4.25 Million USD | 52.25% |
| 2014 Q4 | 450 Thousand USD | 110.58% |
| 2014 FY | -19.11 Million USD | 53.55% |
| 2013 Q1 | -9.63 Million USD | 38.85% |
| 2013 Q2 | -12.45 Million USD | -29.28% |
| 2013 Q3 | -9.21 Million USD | 25.99% |
| 2013 Q4 | -9.85 Million USD | -6.91% |
| 2013 FY | -41.14 Million USD | -34.85% |
| 2012 Q4 | -15.74 Million USD | -630.38% |
| 2012 FY | -30.51 Million USD | -91.82% |
| 2012 Q1 | -7.25 Million USD | -47.84% |
| 2012 Q3 | -2.15 Million USD | 59.77% |
| 2012 Q2 | -5.35 Million USD | 26.08% |
| 2011 Q1 | -3.37 Million USD | -979.55% |
| 2011 Q2 | -5.29 Million USD | -56.61% |
| 2011 Q3 | -2.33 Million USD | 55.91% |
| 2011 Q4 | -4.9 Million USD | -110.2% |
| 2011 FY | -15.9 Million USD | -123.29% |
| 2010 Q3 | -2.46 Million USD | 24.33% |
| 2010 Q1 | -1.1 Million USD | 76.72% |
| 2010 Q4 | -313 Thousand USD | 87.28% |
| 2010 FY | -7.12 Million USD | 61.21% |
| 2010 Q2 | -3.25 Million USD | -195.55% |
| 2009 FY | -18.36 Million USD | 58.23% |
| 2009 Q1 | -5.64 Million USD | 11.57% |
| 2009 Q4 | -4.72 Million USD | 14.0% |
| 2009 Q3 | -5.49 Million USD | -119.41% |
| 2009 Q2 | -2.5 Million USD | 55.63% |
| 2008 Q4 | -6.38 Million USD | 0.0% |
| 2008 FY | -43.97 Million USD | -14.68% |
| 2008 Q1 | -13.1 Million USD | 0.0% |
| 2007 Q1 | -5.44 Million USD | 0.0% |
| 2007 FY | -38.34 Million USD | -103.78% |
| 2006 FY | -18.81 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -54.667% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 66.796% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 73.249% |
| Organovo Holdings, Inc. | -15.08 Million USD | -351.206% |